Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.47 |
| ▸ | SETD2 | Q9BYW2 | 7/20 | 0.44 |
| ▸ | NSD2 | O96028 | 1/20 | 0.42 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.42 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | HTR1B | P28222 | 1/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | PBK | Q96KB5 | 4/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | CHEK1 | O14757 | 4/20 | 0.41 |
| ▸ | CDK2AP1 | O14519 | 1/20 | 0.41 |
| ▸ | PLA2G7 | Q13093 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3599119 | 1.00 | MAPK1 (0.47) | MAPK1OPRK1SETD2NSD2CYP2C8 | |
| SCHEMBL3599117 | 1.00 | MAPK1 (0.47) | MAPK1OPRK1SETD2NSD2CYP2C8 | |
| SCHEMBL3602154 | 0.93 | SMYD3 (0.46) | MAPK1OPRK1SETD2NSD2CYP2C8 | |
| SCHEMBL3608204 | 0.93 | SMYD3 (0.46) | MAPK1OPRK1SETD2NSD2CYP2C8 | |
| SCHEMBL3602150 | 0.93 | SMYD3 (0.46) | MAPK1OPRK1SETD2NSD2CYP2C8 | |
| SCHEMBL3607941 | 0.87 | SETD2 (0.52) | MAPK1OPRK1SETD2NSD2CYP2C8 | |
| SCHEMBL3607939 | 0.87 | SETD2 (0.52) | MAPK1OPRK1SETD2NSD2CYP2C8 | |
| Trifluoroacetic Acid SCHEMBL3608425 | 0.86 | SMYD3 (0.40) | SETD2NSD2CYP2C8DRD2HTR1B | |
| Trifluoroacetic Acid SCHEMBL3607352 | 0.86 | SMYD3 (0.40) | SETD2NSD2CYP2C8DRD2HTR1B | |
| SCHEMBL25532114 | 0.84 | MAPK1 (0.47) | MAPK1OPRK1SETD2NSD2PBK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | claimed |
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2010-02-11 | — | — | US | disclosed |
| WO-2009158375-A1 | AZA-CYLIC INDOLE- 2 -CARBOXAMIDES AND METHODS OF USE THEREOF | ABBOTT LABORATORIES (US) | 2009-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100035862-A1 | NOVEL AZA-CYCLIC INDOLE-2-CARBOXAMIDES AND METHODS OF USE THEREOF | IDO2, IDO1, INMT | MAPK1 4292/4885OPRK1 609/4885SETD2 2175/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.